Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569272 | 1.00 | HPGD (0.65) | HPGDALDH1A1GAAL3MBTL1RAB9A | |
| SCHEMBL4336939 | 0.88 | HPGD (0.61) | HPGDALDH1A1GAAL3MBTL1RAB9A | |
| SCHEMBL7432274 | 0.88 | HPGD (0.63) | HPGDALDH1A1GAAL3MBTL1RAB9A | |
| SCHEMBL12668076 | 0.88 | HPGD (0.70) | HPGDALDH1A1GAAL3MBTL1RAB9A | |
| SCHEMBL1009309 | 0.86 | TP53 (0.62) | HPGDALDH1A1GAAL3MBTL1RAB9A | |
| SCHEMBL3365627 | 0.85 | ALDH1A1 (0.70) | HPGDALDH1A1GAAL3MBTL1TSHR | |
| SCHEMBL3365457 | 0.85 | ALDH1A1 (0.70) | HPGDALDH1A1GAAL3MBTL1TSHR | |
| SCHEMBL1777398 | 0.85 | ALDH1A1 (0.70) | HPGDALDH1A1GAAL3MBTL1TSHR | |
| SCHEMBL11117715 | 0.79 | ALDH1A1 (0.59) | HPGDALDH1A1GAAL3MBTL1KMT2A | |
| SCHEMBL20901695 | 0.79 | ENPP2 (0.54) | HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032542-A1 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | IDING HANS | 2007-02-08 | — | — | US | disclosed |
| US-7148362-B2 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1664323-A1 | ENZYMATIC SYNTHESIS OF ENATIOPURE INTERMEDIATES BY MEANS OF CHOLESTEROLESTERASE FROM YEASTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026373-A1 | ENZYMATIC SYNTHESIS OF ENATIOPURE INTERMEDIATES BY MEANS OF CHOLESTEROLESTERASE FROM YEASTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | WO | disclosed |
| US-20050065204-A1 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065204-A1 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | MAOB, MAOA, CYP1B1 | HPGD 276/4885ALDH1A1 249/4885GAA 478/4885 |
| US-20070032542-A1 | Process for the preparation of enantiopure pyrrolidin-2-one derivatives | MAOB, MAOA, CYP1B1 | HPGD 276/4885ALDH1A1 249/4885GAA 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.